Navigation Links
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Date:3/11/2009

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). INT131-007 is a 24 week, high dose active comparator (45mg Actos(R)) and placebo controlled study of INT131 at four doses in poorly controlled Type 2 diabetics.

"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with inadequately controlled type 2 diabetes mellitus (T2DM), said Alex DePaoli, M.D. InteKrin's Chief Medical Officer. "This Phase 2b study will provide critical efficacy, safety, and tolerability data to allow differentiation of INT131 from Actos(R) and inform dose selection for the Phase 3 program".

"InteKrin is very pleased to achieve this critical development milestone for INT131," remarked InteKrin's President and CEO, Denny Lanfear. "We anticipate having results from INT131-007 in the second half of this year concurrent with completion of all nonclinical and CMC efforts, enabling initiation of the INT131 Phase 3 program in 1H2010."

INT131 is a selective PPAR gamma modulator which has consistently demonstrated the separation of the powerful PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects. INT131 is well positioned to fulfill the unmet medical need for patients requiring safe treatment of insulin resistance, a key etiological feature in the onset and subsequent progression of T2DM, which remains inadequately addressed by current therapies.

About InteKrin (www.InteKrin.com):

InteKrin Therapeu
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... ARBOR, Mich., Nov. 9 Thomson Reuters ... a leading clinical surveillance solution that enables hospitals to ... improve clinical quality and reduce total cost of treatment. ... at no additional cost. , CareFocus 2.0 ...
... Nov. 9 Arcadia Resources, Inc. (NYSE Amex: ... care services under the Arcadia HealthCare(SM) brand, has appointed ... will replace Tres Lund who announced his resignation from ... http://www.newscom.com/cgi-bin/prnh/20091109/DE07521 ) , Goldsmith is the Daniel ...
Cached Medicine Technology:Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3
(Date:8/23/2014)... (PRWEB) August 23, 2014 Youth substance ... Texas. It’s no different in Houston, TX. Substance abuse ... falling victim to drug and alcohol dependency in higher ... looking to beat substance abuse, but don’t know where ... treatment facility can be a challenge because most treatment ...
(Date:8/23/2014)... 23, 2014 Teen substance abuse ranks as ... Holly Springs, NC. Countless adolescents throughout North Carolina struggle with ... Unfortunately, many never receive professional rehab due to a lack ... to get help. Troubled Teens Holly Springs is a helpline ... local teenage alcohol abusers in Wake County who ...
(Date:8/22/2014)... August 23, 2014 Search Engine ... the first page of search engines and get ... Hosting has recently compared many Linux hosting suppliers ... Bluehost are the most recommended Linux hosting suppliers ... and Europe to buy high quality Linux hosting ...
(Date:8/22/2014)... 2014 Deep Research Report on ... in-depth research report on the Glucose Meter market. ... Glucose Meter definition, classification, application, and industry chain ... covers the international market analysis, including domestic market ... environment & economic situation analysis. The report on ...
(Date:8/22/2014)... Recently, Skmen.com, an experienced supplier of ... bohemian dresses in its online store. Moreover, all these ... to 28% off. All the international clients can obtain ... 2014. , The company’s professional online workers update ... worldwide customers more the latest information about its new ...
Breaking Medicine News(10 mins):Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2
... ACNE TREATMENT EMBRACES DIFFERENCES IN MEN,S,AND WOMEN,S SKIN BY ... TREATMENT SOLUTION, SUMMIT, N.J., Oct. 30 Here,s ... between men and women are no more than skin,deep. ... care product, each,gender will be able to address these ...
... DENVER, Oct. 30 Air Methods Corporation,(Nasdaq: AIRM ) announces the ... Webcast, When: November 6, 2008 @ 4:15 ... Live over the Internet -- Simply log ... address above., Contact: Christine Clarke ...
... common gene variations may be responsible for much of ... New research on the MYH9 geneand its implications for ... the African American populationwill be summarized in a press ... Nephrology,s 41st Annual Meeting and Scientific Exposition in Philadelphia, ...
... Many with Eating Disorders, PHOENIX, Oct. 30 ... disorders are worried about treatment and not,seeking the help ... help for an eating disorder can be very,serious because ... Wall, PhD, director of psychological services at Remuda Ranch,Programs ...
... - Expands Therapy to Broader Patient Population -, ... Inc.,(NYSE: HSP ), a global specialty pharmaceutical ... Food and Drug Administration (FDA),approved a new indication ... This approval allows for use of Precedex in,non-intubated ...
... on a wide range of patient treatment experiences ... and features of ... Altrazeal(TM) -, LAS VEGAS, Oct. 30 ULURU ... application of Altrazeal(TM) -,Transforming Powder Dressing were presented yesterday at a special session,of ...
Cached Medicine News:Health News:Finally ... A Chance for Both Men and Women to Take CTRL(TM) of Their Own Skin! 2Health News:Finally ... A Chance for Both Men and Women to Take CTRL(TM) of Their Own Skin! 3Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 2Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 3Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 4Health News:Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need 2Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 2Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 3Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 4Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 3